The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy

BACKGROUND: Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. OBJECTIVE: The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Paolicelli, Damiano, Iannazzo, Sergio, Santoni, Laura, Iaffaldano, Antonio, Di Lecce, Valentina, Manni, Alessia, Lavolpe, Vito, Tortorella, Carla, D'Onghia, Mariangela, Direnzo, Vita, Puma, Elisa, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938389/
https://www.ncbi.nlm.nih.gov/pubmed/27390865
http://dx.doi.org/10.1371/journal.pone.0159214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938389/
https://www.ncbi.nlm.nih.gov/pubmed/27390865
http://dx.doi.org/10.1371/journal.pone.0159214

Ejemplares similares